Qiagen said this week that it has acquired privately held next-generation sequencing firm Intelligent Bio-Systems for an undisclosed amount as part of a broader strategy to enter the NGS market with a specific focus on clinical sequencing.

Qiagen's CEO Peer Schatz told In Sequence that the company would make use of IBS's existing sequencing platform, the Mini-20, and incorporate that with Qiagen's DNA extraction methods, sample prep, and bioinformatics to create a "complete workflow from A to Z."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.